lundi 14 mai 2012

Recently adopted names for antitumoral compounds (May 2012) - Noms d’antitumoraux adoptés récemment (mai 2012)

Name (nom)
Code name

asparaginase Erwinia chrysanthemi (Erwinaze, Erwinase)
Breaks down the aminoacid asparagine
MDV3100, MDV-3100
synthetic small molecule (signalling inhibitor)
Androgen receptor
BIBF1120, BIBF-1120,
synthetic small molecule (antivascular agent
vascular endothelial growth factor receptor (VEGFR), fibroblast growth factor receptor (FGFR) and platelet derived growth factor receptor (PDGFR)

More on asparaginase Erwinia chrysanthemi

L-asparaginase treatment in acute lymphoblastic leukemia: a focus on Erwinia asparaginase.
Pieters R, Hunger SP, Boos J, Rizzari C, Silverman L, Baruchel A, Goekbuget N, Schrappe M, Pui CH. Cancer. 2011 Jan 15;117(2):238-49.

More on enzalutamide

The evolution of antiandrogens: MDV3100 comes of age. Dumas L, Payne H, Chowdhury S. Expert Rev Anticancer Ther. 2012 Feb;12(2):131-3.

More on nintedanib

Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. Richeldi L, Costabel U, Selman M, Kim DS, Hansell DM, Nicholson AG, Brown KK, Flaherty KR, Noble PW, Raghu G, Brun M, Gupta A, Juhel N, Klüglich M, du Bois RM. N Engl J Med. 2011 Sep 22;365(12):1079-87.

New antiangiogenics in non-small cell lung cancer treatment: Vargatef™ (BIBF 1120) and beyond.
Gori B, Ricciardi S, Fulvi A, Intagliata S, Signore ED, de Marinis F.
Ther Clin Risk Manag. 2011;7:429-40.

Aucun commentaire:

Enregistrer un commentaire